An interventional study of Music therapy in Parkinson's Disease (PD), sponsored by Siegward -M. Elsas. Recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Siegward -M. Elsas · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.
Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 18th largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2026, is one of 49 with no phase, reaches primary completion later than 29 of the 33 other live ones, and was the 83rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–75
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Alain Kaelin · Sites in Switzerland
Ages 50–80
Julien Bally · Sites in Switzerland
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 30 across the 67 interventional studies, 64 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 85 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Siegward -M. Elsas as lead sponsor.
Siegward -M. Elsas has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Parkinson Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831500Julien BallyFeasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | 2026-11 |
| NCT07485218University of Applied Sciences and Arts of Southern SwitzerlandMultidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's Disease | 2026-12 |
| NCT06608875University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT05765110Insel Gruppe AG, University Hospital BernSPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease | 2026-12-31 |
| NCT07802509Klinik ValensDoes Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Parkinson Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to examine whether individual music therapy - involving the slow, gentle bowing of a string instrument, accompanied by the music therapist's singing and lyre playing - can have a relaxing and calming effect on patients with Parkinson's disease and improve anxiety, quality of life, and autonomic dysfunction such as unstable blood pressure.
People with Parkinson's disease often struggle with anxiety, apathy, and depression, which can severely affect their quality of life. These symptoms are usually difficult to treat adequately with medication. They are frequently associated with dysfunction of the autonomic nervous system and a reduced variability of heart rate. Both are common in Parkinson's disease and can provide clues about stress and well-being. A healthy heart does not beat at completely regular intervals; instead, the time between beats constantly changes slightly. This fluctuation is called heart rate variability (HRV).
Primary study outcome will be anxiety. Motivation, depression, individual quality of life, and severity of autonomic symptoms are also assessed using validated questionnaires.
Physical study measures will be HRV, along with stability of blood pressure, intensity of tremor, ability to walk, and also electroencephalography (EEG) to assess brain activity.
A subproject will explore whether listening to emotionally evocative music can specifically influence the brain in patients with Parkinson's disease (as measured by EEG) and autonomic functions (as measured by HRV). The effectiveness of an emotional response will be measured by a questionnaire (the Geneva Emotional Music Scale).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Music therapy
Eight weekly individual sessions of music therapy for patients with Parkinson's disease. Part 1 - Listening to lyre music (10 minutes) Participants listen to emotionally stimulating lyre music. Part 2 - Active playing of a string instrument (20 minutes) Participants perform slow, calm bowing of a low string instrument, the Tenor Chrotta (with a pitch range comparable to the cello), guided and supported by the singing of the music therapist.
Parkinson Anxiety Scale (PAS)
The Parkinson Anxiety Scale (PAS) is a 12-item, Parkinson's disease-specific rating scale that measures anxiety severity across three domains: persistent anxiety, episodic anxiety, and avoidance behavior. Items are rated on a 5-point Likert scale, with higher scores indicating greater anxiety.
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
Geriatric Depression Scale (GDS-15)
The Geriatric Depression Scale-15 is a 15-item self-report questionnaire assessing depressive symptoms in older adults. Total scores range from 0 to 15, with higher scores indicating greater depression severity.
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
Scales for Outcomes in Parkinson's disease - Autonomic Dysfunction (SCOPA-AUT)
The Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) is a 26-item self-report questionnaire assessing autonomic symptoms in patients with Parkinson's disease. Total scores range from 0 to 69, with higher scores indicating greater autonomic dysfunction.
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
General Self-Efficacy Scale (SWE)
The General Self-Efficacy Scale is a 10-item self-report questionnaire assessing optimistic beliefs about coping with difficult demands, problem solving, and adaptation to stressful life events. Total scores range from 10 to 40, with higher scores indicating greater general self-efficacy.
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
Apathy Evaluation Scale (AES)
The Apathy Evaluation Scale (AES) is an 18-item rating scale assessing apathy. Total scores range from 18 to 72, with higher scores indicating greater apathy.
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
Schedule for the Evaluation of Individual Quality of Life (SEIQoL-Q)
The Schedule for the Evaluation of Individual Quality of Life (SEIQoL-Q) is a 24-item rating scale assessing quality of life. Items are rated from from 0% to 100%, with higher scores indicating greater quality of life.
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
Multidimensional Mood Questionnaire (MDBF)
The Multidimensional Mood Questionnaire (MDBF) is a 12-item questionnaire used to assess current well-being before and after a music therapy session. Items are assessed on a 5-point Likert Scale form 1-5, with higher scores indicating stronger moods (positive or negative).
Time frame: from the beginning of a therapy session to the end of a therapy session, on average over 45 minutes
Heart Rate Variability (HRV)
The degree of heart rate variability correlates with well-being, with lower values indicating an increase in stress and anxiety.
Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).
modified Schellong test (orthostatic function)
Continuous measurement of noninvasive blood pressure with the CNAP (Continuous Non-Invasive Arterial Pressure) machine from sitting to standing. Larger drops indicate more severe impairment of orthostatic regulation.
Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).
Timed up and Go Test (TUG)
The Timed up and Go Test (TUG) measures the time in seconds needed to get up from a chair, walk 3 meters forward and back, and get seated again. The shorter the time needed, the better the ability to walk.
Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).
Tremor
Tremor is item number 2.10 from the UPDRS-MDS (United Parkinson's Disease Rating Scale - Movement Disorders Society) questionnaire measuring severity of tremor by a 5 point Likert scale from 0 - 4, with higher scores indication more severe tremor
Time frame: From four weeks before the first treatment (pre-baseline), immediately before the first treatment (baseline), after weeks 4 and 8 of the weekly treatment, and 4 weeks after the end of therapy (follow-up), through study completion, on average 4 months.
Archimedes Spiral
Drawing an Archimedes Spiral measures intensity of tremor; the greater the deviation from a regular spiral, the more severe is the tremor.
Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), and 4 weeks before the 1st treatment, immediately before the 1st treatment, after weeks 4 and 8 of the weekly treatment, and 4 weeks after end of therapy (average 4 months).
Electroencephalography (EEG)
Power of alpha\&theta in cerebral regions and connectivity between cerebral regions will be measured.
Time frame: from onset of a therapy session to the end of a therapy session (avg. 45 min.), during the 1st treatment, and during the last treatment (week 8 of the weekly treatment) (average 2 months).
Geneva Emotional Music Scale (GEMS-9)
The Geneva Emotional Music Scale (GEMS-9) is a 9-item questionnaire which rates the perceived emotions during listening to music, on a 5-point Likert scale from 1-5, with higher scores indicating stronger emotions (positive or negative). This scale is designed to measure how effective a piece of music has been to evoke specific emotions.
Time frame: Some music therapy sessions include 4 sections of 5 min. each, which are designed to evoke specific emotions. At the end of each emotional music section, the GEMS-9 Scale measures how strong the experienced emotions were over the preceding 5 minutes.
Plan to share: Undecided — this requirement is new to the PI and he will have to study its implications before agreeing to it
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 26 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 26 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.